Silencing of cip2a enhances the anti-tumor activity of docetaxel against pc-3 prostate cancer cells

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a human oncoprotein which modulates malignant cellular proliferation. CIP2A is overexpressed in human prostate cancer as well as most ofthe human malignancies. This study aimed to investigate the effects of CIP2A silencing on the sensitivity of PC-3 cells to the docetaxel chemotherapy. PC-3 cells were transfected with CIP2A siRNA. CIP2A mRNA and protein expression were assessed after CIP2A gene silencing by real-time PCR and western blotting. Proliferation and apoptosis of PC-3 cells were analyzed after docetaxel treatment by MTT assay, DAPI staining and flow cytometry, respectively. CIP2A silencing enhanced the sensitivity of PC-3 cells to docetaxel through strengthening cell growth inhibition and apoptosis induced by docetaxel against PC-3 cells. CIP2A silencing may potentiate the cytotoxic effects of docetaxel which might be a promising therapeutic approach in prostate cancer treatment

Keywords:

Prostate Cancer , Gene and Cancer , Solid Tumors , Cancer Treatment and Management , Targeted Cancer Therapy